Lilly launches higher dose vials of weight-loss drug for $150 less than injector penReuters • 02/25/25
Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug accessCNBC • 02/25/25
Lilly launches additional Zepbound vial doses and offers new savings for self-pay patientsPRNewsWire • 02/25/25
Eli Lilly's Breakout Is Nearly Here: Performance Metrics/Bullish Support Remain RobustSeeking Alpha • 02/23/25
This Growth Stock Surged 63% in 2024. Here's Why 2025 Could Bring An Even Bigger Gain.24/7 Wall Street • 02/21/25
Don't Overlook Lilly (LLY) International Revenue Trends While Assessing the StockZacks Investment Research • 02/20/25
Eli Lilly aims to invest in 'big problems hiding in plain sight' using obesity windfallCNBC • 02/20/25
From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugsCNBC • 02/20/25
Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge MistakeThe Motley Fool • 02/15/25